These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 34390854)

  • 1. SCAMP4 is a novel prognostic marker and correlated with the tumor progression and immune infiltration in glioma.
    Ge X; Wang Z; Jiang R; Ren S; Wang W; Wu B; Zhang Y; Liu Q
    Int J Biochem Cell Biol; 2021 Oct; 139():106054. PubMed ID: 34390854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
    Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
    Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Transcriptional Signature of PDGF-DD Activated Natural Killer Cells Predicts More Favorable Prognosis in Low-Grade Glioma.
    Sun Y; Sedgwick AJ; Palarasah Y; Mangiola S; Barrow AD
    Front Immunol; 2021; 12():668391. PubMed ID: 34539622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EFNA1 is a potential key gene that correlates with immune infiltration in low-grade glioma.
    Hao YP; Wang WY; Qiao Q; Li G
    Medicine (Baltimore); 2021 Jun; 100(22):e26188. PubMed ID: 34087884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RELL1, a novel oncogene, accelerates tumor progression and regulates immune infiltrates in glioma.
    Jin X; Xie H; Liu X; Shen Q; Wang Z; Hao H; Gu Y
    Int Immunopharmacol; 2020 Oct; 87():106707. PubMed ID: 32683297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Profiles of immune-related genes and immune cell infiltration in the tumor microenvironment of diffuse lower-grade gliomas.
    Deng X; Lin D; Zhang X; Shen X; Yang Z; Yang L; Lu X; Yu L; Zhang N; Lin J
    J Cell Physiol; 2020 Oct; 235(10):7321-7331. PubMed ID: 32162312
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Qu S; Liu J; Wang H
    Front Immunol; 2021; 12():648416. PubMed ID: 33889156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of immune phenotype with IDH mutation in diffuse glioma.
    Berghoff AS; Kiesel B; Widhalm G; Wilhelm D; Rajky O; Kurscheid S; Kresl P; Wöhrer A; Marosi C; Hegi ME; Preusser M
    Neuro Oncol; 2017 Oct; 19(11):1460-1468. PubMed ID: 28531337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
    Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
    J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the Clinical Significance of PD-1/PD-Ls Expression and Methylation in Patients With Low-Grade Glioma.
    Mei J; Cai Y; Xu R; Yang X; Zhou W; Wang H; Liu C
    Technol Cancer Res Treat; 2021; 20():15330338211011970. PubMed ID: 33955303
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Hu Z; Qu S
    Front Immunol; 2021; 12():683572. PubMed ID: 34267752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ARL3 is downregulated and acts as a prognostic biomarker in glioma.
    Wang Y; Zhao W; Liu X; Guan G; Zhuang M
    J Transl Med; 2019 Jun; 17(1):210. PubMed ID: 31234870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
    Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
    Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Biomarker ZNF311 and Its Correlation With Tumor Progression and Immune Infiltrates in Glioma.
    Ge X; Jiang S; Wang Z; Hu N; Jiang R; Cai Z; Wu B; Zhang Y; Gong P
    World Neurosurg; 2021 Jul; 151():e37-e46. PubMed ID: 33746099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Gene Expression Signature in Patients With Distinct Glioma Grades.
    Ait Ssi S; Chraa D; El Azhary K; Sahraoui S; Olive D; Badou A
    Front Immunol; 2021; 12():685213. PubMed ID: 34539626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serine Incorporator 2 (SERINC2) Expression Predicts an Unfavorable Prognosis of Low-Grade Glioma (LGG): Evidence from Bioinformatics Analysis.
    Qi C; Lei L; Hu J; Wang G; Liu J; Ou S
    J Mol Neurosci; 2020 Oct; 70(10):1521-1532. PubMed ID: 32642801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RFC2: a prognosis biomarker correlated with the immune signature in diffuse lower-grade gliomas.
    Zhao X; Wang Y; Li J; Qu F; Fu X; Liu S; Wang X; Xie Y; Zhang X
    Sci Rep; 2022 Feb; 12(1):3122. PubMed ID: 35210438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive exploration of tumor mutational burden and immune infiltration in diffuse glioma.
    Kang K; Xie F; Wu Y; Wang Z; Wang L; Long J; Lian X; Zhang F
    Int Immunopharmacol; 2021 Jul; 96():107610. PubMed ID: 33848908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TGF-β Score based on
    Zhang W; Yan Z; Zhao F; He Q; Xu H
    Recent Pat Anticancer Drug Discov; 2024; 19(5):610-621. PubMed ID: 37718518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orphan nuclear receptor TLX promotes immunosuppression via its transcriptional activation of PD-L1 in glioma.
    Zhou J; Pei X; Yang Y; Wang Z; Gao W; Ye R; Zhang X; Liu J; Liu Z; Yang X; Tao J; Gu C; Hu W; Chan FL; Li X; Mao J; Wu D
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33858847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.